THE EFFICACY OF THE STANDARD TRIPLE ANTI HELICOBACTER PYLORI THERAPY IN ENDOSCOPY–PROVEN DUODENAL AND GASTRIC ULCERS

Authors

  • Mohammad A. Al-Sheikhani Kurdistan Center for Gastrohepatology and Hepatology; Department of Medicine, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
  • Bnar Sardar Saida Shar Hospital, Directory of Health, Ministry of Health, Sulaimani, Kurdistan Region, Iraq.

DOI:

https://doi.org/10.17656/jsmc.10122

Keywords:

H. pylori, Triple therapy, Gastric ulcer, Duodenal ulcer

Abstract

Background

Helicobacter pylori infection has a high global prevalence and carries a significant disease burden. For more than 10 years now, the recommended therapy worldwide for eradication has been a standard triple therapy with amoxicillin, clarithromycine and a proton pump inhibitor. The success of this therapy has been declined in the recent years due to many factors.

Objectives

To determine the efficacy of the current standard triple anti-Helicobacter pylori treatment in Slemani.

Patients and Methods

This is a prospective study enrolling 62 patients carried out at Shar teaching hospital endoscopy department during a period from January 2015 through January 2016. Patients with gastric and duodenal ulcer underwent biopsy taken from body and antrum of their stomach (one sample from each part), along with stool samples for monoclonal stool antigen testing. They were subjected to standard triple therapy for 2 weeks. After 4 weeks of completion of the treatment they underwent stool antigen test to confirm the eradication.

Results

The eradication rate was 58%. Male gender, smoking, diabetes and non-steroidal anti inflammatory dug use had reduced chance of cure.

Conclusion

The eradication rate was low in our locality for the standard triple therapy. Possibly due to many factors, including rising numbers of antibiotic resistance, smoking, poor compliance and comorbidities like diabetes mellitus.

References

Malfertheiner P, Megraud F, O‘Morain CA et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. DOI: https://doi.org/10.1136/gutjnl-2012-302084

Jafri NS, Hornung CA, Howden CW, et al. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med . 2008 Jun 17;148(12):923-31. Epub 2008 May 19 DOI: https://doi.org/10.7326/0003-4819-148-12-200806170-00226

Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:Epub ahead of print. DOI: https://doi.org/10.4161/gmic.25930

Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. et all. Review article: the global emergence of Helicobacter pylori antibiotic resistance;Aliment Pharmacol Ther. 2016 Feb; 43(4): 514–533.

Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274–279. DOI: https://doi.org/10.1111/hel.12046

Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206–214. DOI: https://doi.org/10.1111/hel.12031

De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother. 2007;59:783–785. DOI: https://doi.org/10.1093/jac/dkm005

Garza E, Guillermo Ignacio, Héctor Jesús , Francisco Javier. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014 Feb 14; 20(6): 1438–1449 . DOI: https://doi.org/10.3748/wjg.v20.i6.1438

Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211–223. DOI: https://doi.org/10.1517/14656566.2013.763926

Alsohaibani F, Alashgar H, Alkahtani K, et al. prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015;21:220-5 DOI: https://doi.org/10.4103/1319-3767.161647

Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. 2011. DOI: https://doi.org/10.1016/S0016-5085(12)60549-6

Eun Jeong Gong, Sung-Cheol Yun, Hwoon-Yong Jung, et al. Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change? J Korean Med Sci. 2014 May;29(5):704-713. English DOI: https://doi.org/10.3346/jkms.2014.29.5.704

Shiota S, Rita Reddy, Abeer Alsarraj,et al. Graham, Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans, September 2015 Volume 13, Issue 9, Pages 1616–1624. DOI: https://doi.org/10.1016/j.cgh.2015.02.005

Thung. Global emergence of Helicobacter pylori antibiotic resistance. Aliment pharmacol Ther 2016; 43: 514-533. DOI: https://doi.org/10.1111/apt.13497

J. P. Gisbert; X. Calvet, The Effectiveness of Standard Triple Therapy for Helicobacter pylori Has Not Changed Over the Last Decade, But it is Not Good Enough, ,Aliment Pharmacol Ther. 2011;34(11):1255-1268. DOI: https://doi.org/10.1111/j.1365-2036.2011.04887.x

Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet, 2011 Aug 6;378(9790):507-14. DOI: https://doi.org/10.1016/S0140-6736(11)60825-8

Vakil N, Lanza F, Schwartz H. Seven-day therapy for Helicobacterpylori in the United States. AlimentPharmacol Ther 2004; 20: 99–107. DOI: https://doi.org/10.1111/j.1365-2036.2004.02029.x

Tursi A, Elisei W, Giorgetti G, et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. Panminerva Medica [2014, 56(1):57-61]

Namiot DB, Leszczynska K, Namiot Z. Smoking and drinking habits are important predictors of Helicobacter pylori Eradication. Advances in Medical Sciences. 2008, 53(2): 310-15. DOI: https://doi.org/10.2478/v10039-008-0043-7

Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217-224 DOI: https://doi.org/10.1016/j.amjmed.2005.10.003

Demir M., Gokturk HS, Ozturk NA et al. Clarithromycine resistance and efficacy of Clarithromycine-containing triple eradication therapy for Helicobacter Pylori infection in type 2 diabetes mellitus patients. Southern Medical Journal 2009;102(11):1116-1120. DOI: https://doi.org/10.1097/SMJ.0b013e3181bca538

Sargyn M, Oya Uygur Bairamicli, Haluk Sargin et al. Type 2 diabetes mellitus affects eradication rate Helicobacter pylori. World J Gastroenterol, 2003 May 15; 9(5) 1126-1128. DOI: https://doi.org/10.3748/wjg.v9.i5.1126

Published

2017-08-15

How to Cite

1.
Al-Sheikhani M, Saida B. THE EFFICACY OF THE STANDARD TRIPLE ANTI HELICOBACTER PYLORI THERAPY IN ENDOSCOPY–PROVEN DUODENAL AND GASTRIC ULCERS. JSMC [Internet]. 2017 Aug. 15 [cited 2024 Jul. 24];7(2):205-10. Available from: https://jsmc.univsul.edu.iq/index.php/jsmc/article/view/jsmc-10122

Similar Articles

1-10 of 76

You may also start an advanced similarity search for this article.